The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -7.54 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 2.71 — flag raised, worth a closer lookWatch
- Earnings quality 65/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Syndax Pharmaceuticals Inc reports it. History and quarterly detail are in the app.
- Net Product Revenues$124.8M
- Collaboration Revenue$42.4M
- Milestone Revenue$5.1M
Leadership changes
From Syndax Pharmaceuticals Inc's own filings, the day they're filed.
- Aleksandra Rizo · Directors · appointmenteff. 2024-05-15
- Briggs W. Morrison · departureeff. 2024-05-14
- Steve Sabus · Chief Commercial Officer · departureeff. 2024-03-15
Latest filings
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-06-04
- DEF 14A · Annual proxy (pay & governance)2026-04-30
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Syndax Pharmaceuticals Inc, every answer cited🔒
- The Intelligence Brief — added when Syndax Pharmaceuticals Inc's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.